Vivos stockholders elect all director nominees and approve 2024 equity plan at annual meeting

Vivos Therapeutics, Inc.

Six directors elected: Huntsman, Green, Krammer, Lindsay, Sokolow, Thompson; each received ~1.1M for, ~155-193K withheld.
2024 Omnibus Equity Incentive Plan approved with 957,268 for, 313,560 against, 17,747 abstentions.
Ratification of Moss Adams LLP as auditor for FY2024 passed with 2,496,723 for, 162,219 against, 35,623 abstentions.
Approximately 2.7M of 4.8M outstanding shares voted, constituting a quorum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.